No Data
No Data
Dean Diagnosis: Report for the first quarter of 2025
Dian Diagnostics Group (300244.SZ): A net loss of 21.0056 million yuan in the first quarter.
Glory Financial reported on April 28 that Dian Diagnostics Group (300244.SZ) announced its Q1 2025 report, with revenue of 2.365 billion yuan, a year-on-year decrease of 20.45%; net income attributable to shareholders of the listed company was -21.0056 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -26.3058 million yuan; EPS was -0.0344 yuan.
Dian Diagnostics Group (300244.SZ) is projected to shift from a profit to a loss of 0.357 billion yuan in 2024, with a proposed dividend of 2.5 yuan per share.
On April 23, Gelonghui reported that Dian Diagnostics Group (300244.SZ) released its 2024 annual report. During the reporting period, the company achieved a revenue of 12.196 billion yuan, a year-on-year decrease of 9.04%. The net income attributable to the parent company was -0.357 billion yuan, a year-on-year decrease of 216.20%. The net income after deducting non-recurring gains and losses was -0.38 billion yuan, a year-on-year decrease of 228.96%. During the reporting period, the diagnostic services Business achieved a revenue of 4.52 billion yuan, of which ICL generated a revenue of 4.173 billion yuan. During the reporting period, the company upheld the mission of 'allowing the people to equally Share in health.'
Dean Diagnostics: 2024 Annual Report Summary
Dean Diagnostics: 2024 Annual Report
Lacklustre Performance Is Driving Dian Diagnostics Group Co.,Ltd.'s (SZSE:300244) 30% Price Drop
Dian Diagnostics GroupLtd (SZSE:300244) Adds CN¥362m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 41%
